Tonix Pharmaceuticals Presents Phase 1 Data for Lyme Disease Vaccine

Company outlines plans for adaptive Phase 2 field study of TNX-4800 at World Vaccine Congress

Apr. 1, 2026 at 12:00am

Got story updates? Submit your updates here. ›

Tonix Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced the presentation of Phase 1 data and outlined plans for an adaptive Phase 2 field study of its TNX-4800 vaccine candidate for the prevention of Lyme disease. The announcement was made at the World Vaccine Congress in Washington, D.C.

Why it matters

Lyme disease is a growing public health concern, with cases increasing in many regions. The development of an effective vaccine could help prevent the debilitating effects of this tick-borne illness. Tonix's approach using a long-acting monoclonal antibody represents a novel strategy that could provide protection against Lyme disease.

The details

TNX-4800 is an anti-Borrelia burgdorferi OspA human monoclonal antibody that Tonix is developing as a long-acting vaccine candidate for the prevention of Lyme disease. The company presented positive Phase 1 data for TNX-4800 and announced plans for an adaptive Phase 2 field study to further evaluate the vaccine's safety and efficacy.

  • Tonix presented the Phase 1 data and outlined the Phase 2 plans at the World Vaccine Congress Washington 2026 on April 1, 2026.

The players

Tonix Pharmaceuticals Holding Corp

A clinical-stage biopharmaceutical company developing innovative pharmaceutical and biological products to address public health challenges.

TNX-4800

Tonix's long-acting anti-Borrelia burgdorferi OspA human monoclonal antibody vaccine candidate for the prevention of Lyme disease.

Got photos? Submit your photos here. ›

What’s next

Tonix plans to initiate the adaptive Phase 2 field study of TNX-4800 in the coming months to further evaluate the vaccine's safety and efficacy in preventing Lyme disease.

The takeaway

Tonix's progress with TNX-4800 highlights the ongoing efforts to address the growing public health challenge of Lyme disease through innovative vaccine approaches. If successful, this long-acting monoclonal antibody vaccine could provide an important new tool in the fight against this tick-borne illness.